Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The treatment of HBV related hepatocellular carcinoma has always been a worldwide problem. The aim of this study is to alleviate the progression of hepatitis B related hepatocellular carcinoma by the Chinese medicine "Fu Zheng Jie Du Hua Yu" Principle.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Ditan Hospital

Criteria

Inclusion Criteria:

• Meet the criteria of hepatocellular carcinoma

• Ages Eligible for Study: ≤75 years old;

• Informed consent from the patient.

Exclusion Criteria:

• Serious problem of heart, lung, or kidney with severe dysfunction;

• Pregnant or child breast feeding women;

• Mental or cognitive disorders;

• Participating in other drug trials;

• Who are allergic to the study drug